A5057870738- Hemoglobinopathies and Related Disorders
- HIV/AIDS Research and Interventions
- Iron Metabolism and Disorders
- LGBTQ Health, Identity, and Policy
- Health Literacy and Information Accessibility
- Blood donation and transfusion practices
- Food Security and Health in Diverse Populations
- Social and Behavioral Studies
- Emergency and Acute Care Studies
- Interpreting and Communication in Healthcare
- FinTech, Crowdfunding, Digital Finance
- Healthcare Systems and Technology
- Microfinance and Financial Inclusion
- Ethics in Clinical Research
- Diverse Approaches in Healthcare and Education Studies
- Prenatal Screening and Diagnostics
- COVID-19 Digital Contact Tracing
- Mobile Health and mHealth Applications
- Digital Mental Health Interventions
- Patient-Provider Communication in Healthcare
St. Jude Children's Research Hospital
2019-2024
University of Memphis
2022
Methodist Healthcare
2020
Sickle cell disease (SCD) is an inherited blood disorder causing acute complications and chronic progressive end organ damage. SCD associated with significant morbidity, early mortality, impaired health-related quality of life, increased health care utilization. Hydroxyurea a US Food Drug Administration-approved medication that reduces complications, utilization, costs. However, adherence to hydroxyurea suboptimal. Mobile (mHealth) interventions have the potential improve adherence, but few...
Abstract Hydroxyurea is an efficacious treatment for sickle cell disease (SCD), but adoption low among individuals with SCD. The objective of this study was to examine barriers patients’ adherence hydroxyurea use regimens by using the intentional and unintentional medication nonadherence framework. We interviewed SCD age 15 49.9 years who were participants in Sickle Cell Disease Implementation Consortium (SCDIC) Needs Assessment. framework explains adds granularity understanding unique...
Abstract Sickle cell disease (SCD) is a genetic disorder predominantly affecting people of African descent and associated with significant morbidity mortality. To improve SCD outcomes, the National Heart Lung Blood Institute funded eight centers to participate in Implementation Consortium. Sites were required each recruit 300 individuals SCD, over 20 months. We aim describe recruitment strategies challenges encountered. Participants aged 15–45 years confirmed diagnosis eligible. Descriptive...
Hydroxyurea reduces sickle cell disease (SCD) complications, but medication adherence is low. We tested 2 mobile health (mHealth) interventions targeting determinants of low among patients (InCharge Health) and prescribing providers (HU Toolbox) in a multi-center, non-randomized trial individuals with SCD ages 15-45. compared the percentage days covered (PDC), labs, healthcare utilization, self-reported pain over 24 weeks intervention 12 post-study 24-week preintervention interval. enrolled...
This paper presents the results of a study 300 randomly selected obstetricians and gynaecologists in United Kingdom to assess their perception effect Internet usage by patients on doctor-patient relationship. It also considers extent patients’ usage, quality information need for access training hospitals. Results showed that respondents accepted might lead being better informed than themselves with 40 per cent feeling this may damage Despite 90 believed providing more was good. Respondents...
Hydroxyurea therapy is effective for reducing complications related to sickle cell disease (SCD) and recommended by National Health Lung Blood Institute care guidelines. However, hydroxyurea underutilized, adherence suboptimal. We wanted test a multilevel mobile health (mHealth) intervention increase among patients improve prescribing providers in multicenter clinical trial. In the first 2 study sites, participants were exposed early phases of COVID-19 pandemic, which included disruption...
This study aimed to capture the implementation process of ALIGN Study, (An individualized Pain Plan with Patient and Provider Access for Emergency Department care Sickle Cell Disease). embed Individualized Plans in electronic health record (E-IPP) provide access plan both adult patients sickle cell disease (SCD) emergency department providers when a person SCD comes vaso-occlusive crises.
Mobile health (mHealth) applications have been utilized in chronic diseases to improve medication adherence, though factors driving engagement remain understudied. We previously demonstrated the benefits of mHealth app utilization increasing adherence hydroxyurea. In "Integration into Sickle Cell Disease (SCD) Care Increase Hydroxyurea Utilization" (meSH) study, greater with InCharge Health increased percentage days covered (PDC) for However, influencing were not investigated. This study...
Abstract Introduction Sickle cell disease (SCD) is a chronic condition with progressive neurocognitive deficits. Health literacy (HL) essential during adolescence and young adulthood, as the transition to adult care requires healthcare decisions. HL known be low in SCD; however, relation between general cognitive ability has not been investigated. Methods This cross‐sectional study included adolescent yound adults (AYAs) SCD from two institutions. Logistic regression measured association HL,...
<sec> <title>BACKGROUND</title> Hydroxyurea is an evidence-based disease-modifying therapy for sickle cell disease (SCD) but underutilized. The Integration of Mobile Health into Sickle Cell Disease Care to Increase Utilization (meSH) multicenter study leveraged mHealth deliver targeted interventions patients and providers. SCD studies often underenroll; recruitment strategies in the population are not widely studied. Unanticipated events can negatively impact enrollment, making it important...
Hydroxyurea is an evidence-based disease-modifying therapy for sickle cell disease (SCD) but underutilized. The Integration of Mobile Health into Sickle Cell Disease Care to Increase Utilization (meSH) multicenter study leveraged mHealth deliver targeted interventions patients and providers. SCD studies often underenroll; recruitment strategies in the population are not widely studied. Unanticipated events can negatively impact enrollment, making it important that ensure adequate accrual.
<sec> <title>BACKGROUND</title> Sickle cell disease (SCD) is an inherited blood disorder causing acute complications and chronic progressive end organ damage. SCD associated with significant morbidity, early mortality, impaired health-related quality of life, increased health care utilization. Hydroxyurea a US Food Drug Administration–approved medication that reduces complications, utilization, costs. However, adherence to hydroxyurea suboptimal. Mobile (mHealth) interventions have the...
<sec> <title>BACKGROUND</title> Hydroxyurea therapy is effective in reducing sickle cell disease (SCD)-related complications and recommended by NHLBI care guidelines. However, hydroxyurea underutilized, adherence suboptimal. We are testing a multi-level mobile health (mHealth) intervention to increase among patients prescribing providers multi-center clinical trial. In the first two study sites, participants were exposed early phases of COVID-19 pandemic, which included disruption their...